Stably expressed APOBEC3F has negligible antiviral activity. - Wikidata - wikimedia - TriplyDB

Stably expressed APOBEC3F has negligible antiviral activity.

Stably expressed APOBEC3F has negligible antiviral activity.

http://www.wikidata.org/entity/Q34190587

about

Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all Suppression of APOBEC3-mediated restriction of HIV-1 by Vif 1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n Interaction of APOBEC3A with DNA assessed by atomic force microscopy Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model.HIV restriction by APOBEC3 in humanized mice.Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities.The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict.Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy.HIV Restriction Factors and Mechanisms of Evasion.Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia.Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family.Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.Macaque-tropic human immunodeficiency virus type 1: breaking out of the host restriction factors The assembly of Vif ubiquitin E3 ligase for APOBEC3 degradation.Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection.Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.Differential sensitivity of porcine endogenous retrovirus to APOBEC3-mediated inhibition.Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H.Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy.

P2860

Q24321636-8027166F-C1AB-4666-8CEE-29FCB15DD2A2 Q24612992-BA96DA88-FDB9-4031-A8AA-1AB678B36D2F Q26823568-FCAA2A2F-9C3C-4C4F-BA82-79ABFE5A545E Q27025150-96A9E109-FBCF-4399-867A-961ABD723490 Q27704805-CEDFFE03-4EA0-434D-AB8F-F03891A7B638 Q28481286-AB038803-FCCD-440C-BF9D-BC2FF253D42A Q28539478-BCF0349E-F19C-40AF-8D19-E2E72B433EF6 Q28541264-60E7763E-D5BB-4FB2-90CE-E2315A7F31E0 Q34059564-ABCD276E-1871-49A0-A15C-905030ED1759 Q34352429-6EFEF9F6-0983-4D81-908B-C08EE218D402 Q34649651-55244936-C28C-44E2-ADB5-7615EC8F69BC Q35489088-7046B8BC-F9F6-49B0-894E-09E3EEC77506 Q35627352-BF96BA9C-E6ED-433E-838F-458812267113 Q35697413-21A364F0-DDFB-4AB1-8EFF-AE49D2031662 Q35870897-DBA37FD5-DE27-4573-AF3C-A3D3C940293C Q35902681-B19B2830-9ECB-408D-9146-C75C47BA19D7 Q35945852-76DC0311-0BCE-4ABA-A312-D575EE1D3B16 Q36081987-75E22A72-4AF6-4B62-AF96-BC38AF8C84E9 Q36216511-2DA02A69-84E7-4860-B101-579C63CB4DD6 Q36506765-E5C04551-E266-4D6D-8C62-6BA1C9904101 Q37599297-48BA2E1A-F80B-4FD5-8FB0-F53480427EEC Q38121073-E0A49E89-C2C1-4C94-A702-FCDC88096110 Q38269459-BB481D7F-34DF-472E-813F-076517133CE4 Q38719008-98992242-8942-43D9-94CA-777B2175BAFB Q38725801-9AEE3473-4F7D-4ABC-B567-4877015D560C Q38879828-949BBC46-CB3D-4AAB-8231-9F2EEF5998A8 Q39595254-9580C457-DA52-48AE-A7B2-E534875E25EE Q40709115-BF8F8E48-61C6-4161-96D6-D7F3823B04A2 Q40898035-7142DC0D-2E40-4689-A160-5587400B2960 Q41892602-86ACC145-A32A-4D58-A3CD-ED83855CD3C5 Q42575965-39B7C348-EC54-405A-ABED-57210D2320B9 Q47555946-A8AFE508-9BB6-4539-B7C0-09AD5FFED194 Q47568875-FEF02E47-D0A8-44C0-B015-528AE3361ED9

P2860

Stably expressed APOBEC3F has negligible antiviral activity.

http://www.wikidata.org/entity/Q34190587

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Stably expressed APOBEC3F has negligible antiviral activity.

@ast

Stably expressed APOBEC3F has negligible antiviral activity.

@en

Stably expressed APOBEC3F has negligible antiviral activity.

@nl

type

label

Stably expressed APOBEC3F has negligible antiviral activity.

@ast

Stably expressed APOBEC3F has negligible antiviral activity.

@en

Stably expressed APOBEC3F has negligible antiviral activity.

@nl

prefLabel

Stably expressed APOBEC3F has negligible antiviral activity.

@ast

Stably expressed APOBEC3F has negligible antiviral activity.

@en

Stably expressed APOBEC3F has negligible antiviral activity.

@nl

P1433

Q34190587-DB074341-2357-4CE0-9221-48204C27381F

P1476

Q34190587-98D4B2C1-2F98-4D0B-9519-DA21945EBE33

P2093

Q34190587-12928486-CAFE-462F-937A-293FDDCAD550

Q34190587-1796EEBF-4959-4D1F-B621-A44474903E33

Q34190587-2C956577-313B-4FC9-85E3-21DB3670EE7B

Q34190587-7E1B7455-A99B-4513-8749-467BE8CC2B50

Q34190587-911DDDB4-B995-44B0-AFE5-BD7BB4148615

Q34190587-916CF7EE-6C52-479D-9C16-26FE67EA796D

Q34190587-99097E3F-BB23-4626-B120-08A68314915B

Q34190587-A3A63A24-BDD6-4A90-BAB9-7284106D555C

Q34190587-DC5053D8-97FA-4290-ABDD-BA965A6298E8

P2860

Q34190587-0B703FA5-70F5-462A-91F8-C1F025464108

Q34190587-0DEC7140-692B-4850-BDE1-A3494A1A4E35

Q34190587-12291B39-C132-4726-8BA2-159A65ECC73A

Q34190587-1C3E3BD5-23B7-4386-89F0-4439CC5A1F46

Q34190587-21CFB01D-47B0-4377-A23C-880CD3DBB90D

Q34190587-22CB25F7-3D5C-4F4C-B442-B00318EEEC10

Q34190587-26EA1802-7E1D-4A0C-9B62-6FAD08D7D818

Q34190587-290D8741-B87C-4723-96F4-B5F7E134DE99

Q34190587-2B262E8C-D06D-4006-8C23-EE694695928F

Q34190587-2F1AEAA4-1A45-4208-9E94-0AD602817B3B

P304

Q34190587-7D6B3242-CC0F-4742-9A52-7999A055953A

P31

Q34190587-69A6B0D4-235F-4553-9293-48C5AFB5DA12

P356

Q34190587-54FE084B-3062-4D33-B19C-DA0C914FD1D5

P407

Q34190587-B396781A-6BA1-4C66-AC6D-41AB9D9C6149

P433

Q34190587-3216CC7A-A1BE-4B80-A313-A08DE05F1050

P478

Q34190587-69AF3E38-71C2-4355-8DE5-5243B2AB423B

P577

Q34190587-1507E38A-377F-43EF-B96B-13B5DA5A36AD

P5875

Q34190587-5AA5FF16-DDF0-4437-BD44-2E1048F6ED1F

P698

Q34190587-32176CA2-D37F-44FF-AF10-AD400B473721

P932

Q34190587-7F5FA5F7-F5E7-4E56-A265-42D42A84E9A0

P356

P1433

Journal of Virology

P1476

Stably expressed APOBEC3F has negligible antiviral activity.

@en

P2093

Charles R Brown

http://www.w3.org/2001/XMLSchema#string

Eri Miyagi

http://www.w3.org/2001/XMLSchema#string

Klaus Strebel

http://www.w3.org/2001/XMLSchema#string

Mohammad Khan

http://www.w3.org/2001/XMLSchema#string

Ritu Goila-Gaur

http://www.w3.org/2001/XMLSchema#string

Robert C Walker

http://www.w3.org/2001/XMLSchema#string

Sandra Kao

http://www.w3.org/2001/XMLSchema#string

Sandrine Opi

http://www.w3.org/2001/XMLSchema#string

Vanessa Hirsch

http://www.w3.org/2001/XMLSchema#string

P2860

Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies

APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G

Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity

HIV-1 Vif, APOBEC, and intrinsic immunity

Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages

Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication

Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family

P304

11067-11075

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01249-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45629528

http://www.w3.org/2001/XMLSchema#string

P698

20702622

http://www.w3.org/2001/XMLSchema#string

P932

2953157

http://www.w3.org/2001/XMLSchema#string